El núcleo subtalámico y su potencial utilidad como blanco de estimulación cerebral profunda en trastorno obsesivo-compulsivo

Fabián Cremaschi; Lucas Serrano

doi:10.47924/neurotarget2011280

Autores/as

Fabián Cremaschi Facultad de Ciencias Médicas, Universidad Nacional de Cuyo, Mendoza, Argentina.
Lucas Serrano Facultad de Ciencias Médicas, Universidad Nacional de Cuyo, Mendoza, Argentina.

DOI:

https://doi.org/10.47924/neurotarget2011280

Palabras clave:

Trastorno obsesivo compulsivo, núcleo subtalámico, neuroestimulación

Resumen

El trastorno obsesivo compulsivo (TOC) representa una patología neuropsiquiátrica en la cual, la existencia de un grupo de pacientes con síntomas severos y refractarios a la actual terapia farmacológica y psicológica motiva la búsqueda de nuevas alternativas terapéuticas. En este contexto, la neuroestimulación quirúrgica del núcleo subtalámico (NST), una estructura de fundamental importancia en el control de los circuitos fronto-estriatales de procesamiento motor y límbico, vinculada a la fisiopatología del TOC, ha sido postulada como un tratamiento prometedor para dichos pacientes. Es por ello que el objetivo de la presente revisión se centra en presentar la evidencia clínica actual relacionada a la efectividad de la neuroestimulación en NST para control de síntomas de TOC, así como plantear las controversias existentes en cuanto a posibles eventos adversos psiquiátricos que deberán ser cuidadosamente evaluados en los futuros estudios que se realicen al respecto.

Métricas

Cargando métricas ...

Citas

Kobak KA, Greist JH, Jefferson JW, et al. Behavioral versus pharmacological treatments of obsessive compulsive disorder: a metaanalysis. Psychopharmacology Berl (1998) 136: 205–216.

Eddy KT, Dutra L, Bradley R, Westen D. A multidimensional meta-analysis of psychotherapy and pharmacotherapy for obsessive-compulsive disorder. Clin Psychol Rev (2004) 24: 1011–1030

Pallanti S, Quercioli L. Treatment-refractory obsessive-compulsive disorder: methodological issues, operational definitions and therapeutic lines.Prog Neuropsychopharmacol Biol Psychiatry 2006;30:400-412

Mancebo MC, Eisen JL, Pinto A, et al The Brown longitudinal obsessive compulsive study: treatments received and patient impressions of improvement. J Clin Psychiatry (2006) 67: 1713–1720.

Foa EB, Liebowitz MR, Kozak MJ, et al. Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive- compulsive disorder. Am J Psychiatry (2005) 162: 151–161.

Rotge JY, Guehl D, Dilharreguy B, et al. Provocation of obsessive-compulsive symptoms: a quantitative voxel-based meta-analysis of functional neuroimaging studies. J Psychiatry Neurosci. (2008) 33(5):405-12.

Moresco RM, Pietra L, Henin M, et al Fluvoxamine treatment and D2 receptors: a pet study on OCD drug-naïve patients. Neuropsychopharmacology. (2007) 32(1):197-205.

van der Wee NJ, Stevens H, Hardeman JA, et al Enhanced dopamine trans- porter density in psychotropic-naive patients with obsessive-compulsive disorder shown by [123I]{beta}-CIT SPECT. Am J Psychiatry.(2004)161(12):2201-6.

Saxena S, Gorbis E, O'Neill J, et al Rapid effects of brief intensive cognitive behavioral therapy on brain glucose metabolism in obsessive-compulsive disorder. Mol Psychiatry. (2009) 14(2):197-205.

Lipsman N, Neimat JS, Lozano AM. Deep brain stimulation for treatment-refractory obsessive-compulsive disorder: the search for a valid target. Neurosurgery. (2007) 61(1):1- 11; discussion 11-3. Review.

Saxena S, Brody AL, Schwartz JM, Baxter LR. Neuroimaging and frontal-subcortical circuitry in obsessive-compulsive disorder. Br J Psychiatry (1998) 173(35):26–38.

Mirza Y, O'Neill J, Smith EA, et al. Increased medial thalamic creatine-phosphocreatine found by proton magnetic resonance spectroscopy in children with obsessive-compulsive disorder versus major depression and healthy controls. J Child Neurol. (2006) 21(2):106-11.

Perani D, Colombo C, Bressi S, et. at. [18F]FDG PET study in obsessive-compulsive disorder. A clinical/metabolic correlation study after treatment. Br J Psychiatry. 1995 Feb;166(2):244-50.

Huyser C, Veltman DJ, de Haan E, Boer F. Paediatric obsessive-compulsive disorder, a neurodevelopmental disorder? Evidence from neuroimaging. Neurosci Biobehav Rev. (2009) 33(6):818-30.

Greenberg BD, Gabriels LA, Malone DA Jr, et al Deep brain stimulation of the ventral internal capsule/ventral striatum for obsessive-compulsive disorder: worldwide experience. Mol Psychiatry. (2010) 15(1):64-79.

Abelson JL, Curtis GC, Sagher O, Albucher RC, Harrigan M, Taylor SF .Deep brain stimulation for refractory obsessive-compulsive disorder.Biol Psychiatry (2005) 57: 510–516.

Aouizerate B, Cuny E, Martin-Guehl C, et.al. Deep brain stimulation of the ventral caudate nucleus in the treatment of obsessive-compulsive disorder and major depression. Case report. J Neurosurg. (2004) 101(4):682-6.

Lyons KE, Pahwa R. Long-term benefits in quality of life provided by bilateral subthalamic stimulation in patients with Parkinson disease. J Neurosurg. (2005) 103(2):252-5.

Houeto JL, Welter ML, Bejjani PB, et al Subthalamic stimulation in Parkinson disease: intraoperative predictive factors. Arch Neurol. (2003) 60(5):690-4.

Komotar RJ, Starke RM, Connolly ES, Goodman RR. Pallidal vs subthalamic deep brain stimulation for Parkinson disease. Neurosurgery. (2010) 67(4):N25-7.

Muniz AM, Liu W, Liu H, Lyons KE, Pahwa R, Nobre FF, Nadal J. Assessment of the effects of subthalamic stimulation in Parkinson disease patients by artificial neural network. Conf Proc IEEE Eng Med Biol Soc. 2009;2009:5673-6.

Kelly VE, Israel SM, Samii A, et al Assessing the effects of subthalamic nucleus stimulation on gait and mobility in people with Parkinson disease. Disabil Rehabil. (2010) 32(11):929-36.

Umemura A, Oka Y, Okita K, et al Subthalamic nucleus stimulation for Parkinson disease with severe medication induced hallucinations or delu- sions. J Neurosurg. (2011) DOI: 10.3171/2011.2.JNS101261.

Alegret M, Junqué C, Valldeoriola F, et al Effects of bilateral subthalamic stimulation on cognitive function in Parkinson disease. Arch Neurol. (2001) 58(8):1223-7. Comment in: Arch Neurol. (2001) 58(8):1205-6.

Mallet L, Mesnage V, Houeto JL, et al Compulsions, Parkinson's disease, and stimulation. Lancet. (2002) 360 (9342):1302-4.

Fontaine D, Mattei V, Borg M, et.al. Effect of subthalamic nucleus stimulation on obsessive-compulsive disorder in a patient with Parkinson disease. Case report. J Neurosurg. (2004) 100(6):1084-6.

Seijo-Zazo E, Seijo-Fernández F, Fernández-González F, et al [A proposed new target for deep brain stimulation in obsessive-compulsive disorder]. [Article in Spanish] Rev Neurol. (2007) 45(7):424-8.

Mallet L, Polosan M, Jaafari N, et al STOC Study Group. Subthalamic nucleus stimulation in severe obsessive-compulsive disorder. N Engl J Med. (2008) 359(20):2121-34. Erratum in: N Engl J Med. (2009) 361(10):1027. Comment in: N Engl J Med. (2009) 360(9):931; author reply 932. N Engl J Med. (2009) 360(9):931-2.

Le Jeune F, Vérin M, N'Diaye K, et al French Stimulation dans le trouble obsessionnel compulsif (STOC) study group. Decrease of prefrontal metabolism after subthalamic stimulation in obsessive-compulsive disorder: a positron emission tomography study. Biol Psychiatry. (2010) 68(11):1016-22.

Schaltenbrand G, Wahren W. Atlas for stereotaxy of the human brain. 2nd ed. Stuttgart: Thieme; 1977.

Yelnik J, Percheron G. Subthalamic neurons in primates: a quantitative and comparative analysis. Neuroscience (1979) 4: 1717–43.

Williams PL, Warwick R. The ventral thalamus or subthalamus. In: Williams PL, Warwick R, editors. Gray‟s anatomy. 36th ed. Edinburgh: Churchill Livingstone (1980) 963–5.

Chang HT, Kita H, Kitai ST. The fine structure of the rat subthalamic nucleus: an electron microscopic study. J Comp Neurol (1983) 221: 113–23.

Kita H, Chang HT, Kitai ST. The morphology of intracellularly labeled rat subthalamic neurons: a light microscopic analysis. J Comp Neurol (1983) 215: 245–57.